CRISPR Assays for Protein Detection This review summarizes recent advances in CRISPR–Cas–based strategies for protein detection. Particular focus is placed on recognition element–based approaches, in which antibodies, aptamers, or DNAz...

Can #CRISPR detect more than just DNA and RNA?🧬➡️🧪

In our latest review for @chemistryeurope.bsky.social we dive into the strategies bridging CRISPR technology and protein detection. From Aptamer to enzymatic activity, CRISPR is becoming a truly universal analytical platform

doi.org/10.1002/cmtd...

Synthetic CRISPR Networks Driven by Transcription Factors via Structure-Switching DNA Translators CRISPR-Cas systems have advanced many domains in life sciences, enabling diverse applications in gene editing, diagnostics, and biosensing. Here, we introduce a platform that leverages transcription f...

Thrilled to share our latest work published in @jacs.acspublications.org Great group effort resulting in the developement of DNA translators for transcription factor mediated control of CRISPR-Cas activity. #DNAnanotech #SyntheticBio

Rapid, Single-Step Monitoring of Monoclonal Antibody Bioavailability by Using a TNF-α-Based Multiepitope DNA Nanoswitch Therapeutic drug monitoring (TDM) is increasingly valuable for tailoring personalized therapy, particularly in managing chronic inflammatory diseases where overtreatment can cause significant side effects. Monoclonal antibodies (mAbs), a primary therapeutic approach for these conditions, face challenges from antidrug antibodies (ADAs), which can reduce mAb bioavailability and efficacy. To address these issues, we utilized Tumor Necrosis Factor α (TNF-α) as a binding moiety in a fluorescence-based programmable nanosensor within the NanoHYBRID (NH) platform developed by Ulisse Biomed S.p.A. By directly conjugating TNF-α to DNA probes, we developed a rapid, homogeneous, affinity-based assay capable of detecting multiple mAbs targeting distinct epitopes on the same protein. This NH platform effectively detected therapeutic concentrations of clinically relevant mAbs, such as Infliximab, Adalimumab, and Golimumab, in blood serum samples in a one-step process, bypassing the need for time-intensive washing steps. Moreover, the NH sensor exhibited heightened sensitivity to the presence of ADA, which impacted drug quantification, indicating its utility for monitoring bioavailable mAb levels. Compared to ELISA, the NH platform demonstrated superior sensitivity to ADAs, suggesting its potential as a highly specific, modular solution for TDM. This modular design allows the NH platform to create multiepitope nanosensors capable of measuring bioavailable mAbs in a single step.

I'm excited to launch our presence here with our latest publication in Analytical Chemistry @pubs.acs.org
A multiepitope #DNA nanoswitch to monitor monoclonal #antibody bioavailability — spun out from a collaboration with our industrial partner Ulisse Biomed. #sensing
pubs.acs.org/doi/10.1021/...

That's cool!! May I be added pls?

May I please be added??

I love it!! May I please be added?